Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed
01 févr. 2018 07h35 HE
|
Exosome Diagnostics
Waltham, MA, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US
25 janv. 2018 07h30 HE
|
Exosome Diagnostics
Waltham, MA, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., today announced that it has entered into a preferred provider network agreement with America’s Choice Provider Network...
HIFU for Prostate Cancer Now Available at Chesapeake Urology
23 janv. 2018 10h00 HE
|
HIFU Prostate Services
CHARLOTTE, N.C., Jan. 23, 2018 (GLOBE NEWSWIRE) -- HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, is excited to announce a...
OTraces’ TME Cancer Blood Test Presentation at Innovation Challenge Spurs Investor Interest from JP Morgan Healthcare Conference Participants
11 janv. 2018 13h39 HE
|
OTraces, Inc.
SAN FRANCISCO and BALTIMORE, Jan. 11, 2018 (GLOBE NEWSWIRE) -- OTraces Inc., a Sykesville, Maryland-based cancer diagnostics company with a unique patented and patent-pending blood test which...
Exosome Diagnostics Announces Positive Coverage for EPI from Largest Payor in the Mid-Atlantic Region
08 janv. 2018 13h15 HE
|
Exosome Diagnostics
Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics announced today that the largest private payor in the Mid-Atlantic region has reached a positive coverage decision for its...
Exosome Diagnostics Launches National Sales Team to Support Flagship Test, ExoDx®Prostate(IntelliScore)
03 janv. 2018 07h30 HE
|
Exosome Diagnostics
Waltham, MA, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Expounding upon the very successful regional introduction of the ExoDx Prostate(IntelliScore), or EPI, Exosome Diagnostics is thrilled to announce...
Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network
04 déc. 2017 07h33 HE
|
Exosome Diagnostics
Boston, MA, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that it has executed an agreement for coverage of its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test
27 nov. 2017 08h16 HE
|
Exosome Diagnostics
Boston, MA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the national Medicare price for its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore),...
Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging
23 oct. 2017 19h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development...
HIFU for Prostate Cancer now Available at North Carolina Specialty Hospital in Durham, North Carolina
13 sept. 2017 12h54 HE
|
HIFU Prostate Services
CHARLOTTE, N.C., Sept. 13, 2017 (GLOBE NEWSWIRE) -- HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, has partnered with North...